Overview

Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Status:
Completed

Trial end date:
2007-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the pharmacokinetics (PK) of decitabine administered to patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

Phase:

Phase 1

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Azacitidine
Decitabine